Clinical Trial Update: A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study assessing safety and tolerability of HKI-272 (neratinib) in Japanese subjects with advanced solid tumors; completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• HKI-272 (neratinib)

Snippet

Sponsor: Puma Biotechnology, Inc. | Conditions: Tumors | Phase 1 | Status: COMPLETED | Results posted: 2018-02-19